SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiaks Phase 3 DAYBREAK trial met its primary endpoints for Zenkuda and tabirafusp-ted in wet AMD, with Zenkuda showing six-month dosing durability for many patients and a planned FDA filing. Traders celebrated the data-driven surge and speculated about a short squeeze, while others warned of profit-taking, potential dilution, and the remaining need for FDA approval.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

HBARs sharp rally and surging volume are being linked by traders to IBM-related enterprise AI and digital-identity developments involving Hedera, alongside its broader AI-partner story. Others say the catalyst is unclear and view the move as momentum or a possible short squeeze, with debate over whether gains will hold or invite profit-taking.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quants selection by The Clearing House for its on-chain money initiative is driving attention, with traders framing the deal as a sign of growing bank adoption and renewed interest in the tokens limited supply. The sharp rally has prompted profit-taking and volatility, while some traders question whether the enterprise deal will create direct demand for QNT itself.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Reports that the Trump administration may ease sanctions and release frozen Iranian assets in exchange for nuclear progress drove sharp, headline-led swings in SPY. Traders debated whether the reports signaled a credible deal or were unconfirmed optimism, while some pointed to persistent oil and Treasury-yield pressure.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB shares are under pressure after CEO Chirantan Desai departed for a senior role at Meta shortly before the companys investor day, raising concerns about leadership continuity despite reaffirmed guidance and former CEO Dev Ittycherias return as interim CEO. Traders are divided between viewing the selloff as an overreaction and buying opportunity and worrying that the abrupt transition signals uncertainty about strategy and execution.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius federal defense grant to convert a U.S. EV-battery line to high-energy-density drone cells is the main catalyst, drawing attention to domestic production expansion and potential defense demand. Traders are divided: bulls view the non-dilutive support as validation, while skeptics note it is not a purchase order and cite the long ramp to production as the stocks initial jump faded.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Positive wet-AMD updates from competitors Kodiak and 4D Molecular Therapeutics have pressured OCUL as traders reassess the competitive bar for AXPAXLI. Bulls argue AXPAXLI may offer stronger durability and a regulatory head start, while skeptics question its differentiation and market prospects.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Traders are linking CLFs sharp drop to the proposed Mesabi Metallics steel plant in Iowa, which some fear could compete with Cleveland-Cliffs or threaten its Minnesota leases. Others question the projects financing and feasibility and argue the selloff is driven by shorting rather than a fundamental threat.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ discussion is dominated by volatile trading around Trumps remarks and disputed reports of possible U.S.-Iran sanctions relief and nuclear concessions; the headlines sparked a relief rally, but many traders questioned the sourcing and whether a deal existed. That uncertainty is compounded by concern that rising Treasury yields and oil prices are pressuring tech stocks.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

TTD is drawing attention amid a steep selloff and fresh multi-year lows, with traders linking the pressure to weak earnings guidance, slowing growth and S&P 500 removal-related selling. Sentiment is sharply divided between bearish criticism of management and competitive threats and dip buyers citing the companys cash generation and potential for a rebound; buyout and short-squeeze talk remains speculative.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ARDX After seeing this Ph1 pub on a foreign NHE-3i, I figured I should reinform myself on current progress: https://pubmed.ncbi.nlm.nih.gov/42472689/ 
 
JMKX003002 – Jemincare 
NHE3 inhibitor. FDA cleared US clinical development in Nov 2023, but current P2a (50 pts) remains China-based and no US commercialization partner announced. 
Estimated US impact: ~2031–33+ unless development accelerates/partners. 
 
Also, AP306 – US R1 Therapeutics/Alebund 
Not NHE3, but IMO the most relevant upcoming US hyperphosphatemia competitor. Global P2b underway (168 pts) with US sites; completion/data expected 1H–2Q27. R1 owns ex-Greater China rights. DaVita Venture Group + U.S. Renal Care are investors/backers (not commercial partners). If successful → P3 potentially late ’27. 
Estimated US launch impact: ~2030 (2029–31 range).

Your Friend

Dee Cee

NOT INV ADVICE

Ferrero Rocher

Mrmadchemist

Viktor

jaw02

Checking your browser before accessing pubmed.ncbi.nlm.nih.gov ...

Checking your browser - reCAPTCHA

StockTwits Web

Ardelyx Inc

 After seeing this Ph1 pub on a foreign NHE-3i, I figured I should reinform myself on current progress: 

 
 
JMKX003002 – Jemincare 
NHE3 inhibitor. FDA cleared US clinical development in Nov 2023, but current P2a (50 pts) remains China-based and no US commercialization partner announced. 
Estimated US impact: ~2031–33+ unless development accelerates/partners. 
 
Also, AP306 – US R1 Therapeutics/Alebund 
Not NHE3, but IMO the most relevant upcoming US hyperphosphatemia competitor. Global P2b underway (168 pts) with US sites; completion/data expected 1H–2Q27. R1 owns ex-Greater China rights. DaVita Venture Group + U.S. Renal Care are investors/backers (not commercial partners). If successful → P3 potentially late ’27. 
Estimated US launch impact: ~2030 (2029–31 range).

@Kevorolac AP 306 is a “thing”.  RDX 10531 is arguably more of a thing. 
Makes me muse ( I have zero expertise in this area) that Ardelyx may elect to “monetize” XPHOZAH in TDAPA program, while putting pedal to the metal on 531. 
I’m told our deadline for that decision is year end 2026.?
Also reading about 531 in grok, we are likely going to get an IND within next 3 1/2 months (H2 2026), I’m guessing sooner than later. That would be at worst a mini short squeeze day I’m thinking fwiw.
NIA

Bozo

StockTwits for iOS

 AP 306 is a “thing”.  RDX 10531 is arguably more of a thing. 
Makes me muse ( I have zero expertise in this area) that Ardelyx may elect to “monetize” XPHOZAH in TDAPA program, while putting pedal to the metal on 531. 
I’m told our deadline for that decision is year end 2026.?
Also reading about 531 in grok, we are likely going to get an IND within next 3 1/2 months (H2 2026), I’m guessing sooner than later. That would be at worst a mini short squeeze day I’m thinking fwiw.
NIA

@bernardbaruch ~30 days until q3, investors would be deserving of some positive development

 ~30 days until q3, investors would be deserving of some positive development

@Kevorolac I think they would pr this in real time JMO

 I think they would pr this in real time JMO